Unknown

Dataset Information

0

Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.


ABSTRACT: AIMS/INTRODUCTION:This study evaluated the efficacy and safety of mirogabalin, a novel, potent, selective ligand of the ?2 ? subunit of voltage-dependent Ca2+ channels, for the treatment of diabetic peripheral neuropathic pain (DPNP). MATERIALS AND METHODS:During this double-blind, multisite, placebo-controlled phase III study, Asian patients aged ?20 years with type 1 or 2 diabetes and DPNP were randomized 2:1:1:1 to a placebo, mirogabalin 15, 20 or 30 mg/day for up to 14 weeks, with a 1- to 2-week titration (NCT02318706). The primary endpoint was the change from baseline in average daily pain score (ADPS) at week 14, defined as a weekly average of daily pain (0 = no pain to 10 = worst possible pain, for the past 24 h). RESULTS:Of 834 randomized patients, 330, 164, 165 and 165 received placebo, mirogabalin 15, 20 or 30 mg/day, respectively, and were included in analyses (modified intention-to-treat population, n = 824); 755 (90.5%) completed the study. At week 14, the least squares mean average daily pain score change from baseline was -1.31, -1.34, -1.47 and -1.81, respectively, showing statistical significance for mirogabalin 30 mg/day versus placebo (P = 0.0027). The treatment-emergent adverse events observed were mostly mild-to-moderate in all mirogabalin doses, and the most frequent treatment-emergent adverse events were nasopharyngitis, somnolence, dizziness, peripheral edema and weight increase. CONCLUSIONS:Mirogabalin relieved DPNP in a dose-dependent manner; mirogabalin 30 mg/day showed statistically significant pain relief (vs placebo) in Asian DPNP patients. All doses of mirogabalin tested were well tolerated.

SUBMITTER: Baba M 

PROVIDER: S-EPMC6717827 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7203334 | biostudies-literature
| S-EPMC7232295 | biostudies-literature
| S-EPMC4682474 | biostudies-literature
| S-EPMC10074464 | biostudies-literature
| S-EPMC3766986 | biostudies-other
| S-EPMC4770341 | biostudies-literature
| S-EPMC6244661 | biostudies-literature
| S-EPMC8064362 | biostudies-literature
| S-EPMC4014905 | biostudies-literature
| S-EPMC7478715 | biostudies-literature